Accessibility links

Breaking News

Venom Experts Say Global Snakebite Toll Far Exceeds Estimates

FILE - A Naja Ashei, a giant spitting cobra measuring nearly 9 feet and carrying enough venom to kill at least 15 people, is seen in this picture released by conservation group WildlifeDirect.

Venom specialists said Wednesday that diseases and disabilities caused by snakebites are far higher than official global health estimates suggest and that anti-venom stocks are running dangerously low.

In a joint statement after a five-day conference in Britain, the international experts said snakebites kill more people than all other so-called Neglected Tropical Diseases combined, yet get little attention or funding from the World Health Organization or from governments.

Citing new evidence from a study in India and Bangladesh, the experts said about 46,000 people die annually of snakebites in India, plus another 6,000 in Bangladesh. The WHO estimates the annual death toll in India from snake bites is 10,000.

"Snakebite ... is almost completely ignored and grossly underestimated," said Alan Harvey, head of the International Society of Toxinology, who led the meeting. "WHO and governments need to ... rank snakebite where it belongs — as a very real public health and medical concern which needs funding, training and focus."

Bites from snakes such as cobras, mambas and vipers mainly affect people living in rural areas of sub-Saharan Africa, South Asia and Southeast Asia with scant health facilities nearby.

Anti-venom treatment can cost between $250 and $500, the experts said, meaning many victims either seek no treatment at all or go to local witch doctors or herbalists.

Despite high death rates, the WHO in 2013 downgraded snakebite to a "neglected condition" with no formal program on how to address it as a health threat, the experts said.

The specialists also warned that anti-venom stocks are running "dangerously low" in many risk areas and said there is a "real crisis in the quantity and quality of antivenins in rural areas, where they are needed most."

Even where anti-venom stocks are good and of high quality, there is often a shortage of medical staff trained in how to administer them safely or effectively, they said.